Literature DB >> 16739211

Use of computerized assessment to predict neuropsychological functioning and emotional distress in patients with systemic lupus erythematosus.

Tresa M Roebuck-Spencer1, Cheryl Yarboro, Miroslawa Nowak, Kazuki Takada, Geneva Jacobs, Larissa Lapteva, Thomas Weickert, Bruce Volpe, Betty Diamond, Gabor Illei, Joseph Bleiberg.   

Abstract

OBJECTIVE: Cognitive dysfunction and neuropsychiatric disturbance are common in systemic lupus erythematosus (SLE). This study addressed the ability of the Automated Neuropsychological Assessment Metrics (ANAM), a computerized cognitive testing battery consisting of cognitive subtests, a sleepiness rating scale, and a mood scale, to predict neuropsychological status in patients with SLE.
METHODS: Sixty individuals with SLE and no overt neuropsychiatric symptoms were administered ANAM to determine its validity as a screening measure of cognitive dysfunction and emotional distress in SLE.
RESULTS: Performance on ANAM was compared with results of a consecutively administered, 2-hour battery of traditional neuropsychological tests and the Beck Depression Inventory II (BDI-II). Individual ANAM cognitive test scores were significantly correlated with most neuropsychological tests, particularly those measuring psychomotor processing speed and executive functioning. Using logistic regression, ANAM cognitive subtests successfully predicted individuals with SLE who had probable versus no impairment after controlling for premorbid levels of cognitive ability. Sensitivity of group classification was 76.2% and specificity was 82.8%, with 80% correct classification overall. ANAM's ability to predict neuropsychological functioning remained even after controlling for subjective reports of depressed mood and current sleepiness. Further, the ANAM mood scale was significantly correlated with the BDI-II (r = 0.67, P < 0.001), indicating its potential future use as a screening tool for emotional distress.
CONCLUSION: ANAM shows promise as a time- and cost-efficient tool for screening and monitoring cognitive and emotional functioning in SLE, and can indicate when a more thorough neuropsychological investigation is warranted.

Entities:  

Mesh:

Year:  2006        PMID: 16739211     DOI: 10.1002/art.21992

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  23 in total

1.  Performance of the Automated Neuropsychological Assessment Metrics (ANAM) in detecting cognitive impairment in heart failure patients.

Authors:  Susan S Xie; Carly M Goldstein; Emily C Gathright; John Gunstad; Mary A Dolansky; Joseph Redle; Joel W Hughes
Journal:  Heart Lung       Date:  2015 Sep-Oct       Impact factor: 2.210

2.  Metabolic and microstructural alterations in the SLE brain correlate with cognitive impairment.

Authors:  Meggan Mackay; An Vo; Chris C Tang; Michael Small; Erik W Anderson; Elisabeth J Ploran; Justin Storbeck; Brittany Bascetta; Simran Kang; Cynthia Aranow; Carl Sartori; Philip Watson; Bruce T Volpe; Betty Diamond; David Eidelberg
Journal:  JCI Insight       Date:  2019-01-10

3.  Validation of the Pediatric Automated Neuropsychological Assessment Metrics in childhood-onset systemic lupus erythematosus.

Authors:  Hermine I Brunner; Marisa S Klein-Gitelman; Frank Zelko; Erin C Thomas; Jessica Hummel; Shannen M Nelson; Jennifer Huggins; Megan L Curran; Tresa Roebuck-Spencer; Dean W Beebe; Jun Ying
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-03       Impact factor: 4.794

Review 4.  Cognitive Dysfunction in Systemic Lupus Erythematosus: A Case for Initiating Trials.

Authors:  Nina Kello; Erik Anderson; Betty Diamond
Journal:  Arthritis Rheumatol       Date:  2019-08-07       Impact factor: 10.995

Review 5.  Integrative neuroscience approach to neuropsychiatric lupus.

Authors:  Patricio T Huerta; Elizabeth L Gibson; Carson Rey; Tomás S Huerta
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

6.  Antibodies against N-methyl-D-aspartate receptors in patients with systemic lupus erythematosus without major neuropsychiatric syndromes.

Authors:  Elizabeth Kozora; Sterling G West; Steven F Maier; Christopher M Filley; David B Arciniegas; Mark Brown; David Miller; Alex Grimm; Lening Zhang
Journal:  J Neurol Sci       Date:  2010-05-23       Impact factor: 3.181

7.  Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial.

Authors:  Michelle Petri; Mohammad Naqibuddin; Margaret Sampedro; Roald Omdal; Kathryn A Carson
Journal:  Semin Arthritis Rheum       Date:  2011-04-01       Impact factor: 5.532

8.  Alterations in Blood-Brain Barrier Permeability in Patients with Systemic Lupus Erythematosus.

Authors:  J M Chi; M Mackay; A Hoang; K Cheng; C Aranow; J Ivanidze; B Volpe; B Diamond; P C Sanelli
Journal:  AJNR Am J Neuroradiol       Date:  2019-02-21       Impact factor: 3.825

9.  Cognitive Performance Scores for the Pediatric Automated Neuropsychological Assessment Metrics in Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Patricia Vega-Fernandez; Shana Vanderburgh White; Frank Zelko; Natasha M Ruth; Deborah M Levy; Eyal Muscal; Marisa S Klein-Gitelman; Adam M Huber; Lori B Tucker; Tresa Roebuck-Spencer; Jun Ying; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-08       Impact factor: 4.794

Review 10.  Neurocognitive impairment in children and adolescents with systemic lupus erythematosus.

Authors:  Deborah M Levy; Stacy P Ardoin; Laura E Schanberg
Journal:  Nat Clin Pract Rheumatol       Date:  2009-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.